Globus Medical - GMED Stock Forecast, Price & News

8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Globus Medical in the last year. There are currently 1 hold rating and 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" GMED shares.
View GMED analyst ratings or view top-rated stocks.

8 equities research analysts have issued 1-year price targets for Globus Medical's shares. Their GMED share price forecasts range from $71.00 to $91.00. On average, they expect the company's stock price to reach $79.00 in the next year. This suggests a possible upside of 1.4% from the stock's current price.
View analysts price targets for GMED or view top-rated stocks among Wall Street analysts.

Globus Medical's stock was trading at $74.27 at the beginning of 2023. Since then, GMED stock has increased by 4.9% and is now trading at $77.88.
View the best growth stocks for 2023 here.

Globus Medical saw a decrease in short interest during the month of December. As of December 30th, there was short interest totaling 4,750,000 shares, a decrease of 5.6% from the December 15th total of 5,030,000 shares. Based on an average daily volume of 588,800 shares, the days-to-cover ratio is currently 8.1 days. Approximately 6.2% of the shares of the company are sold short.
View Globus Medical's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 21st 2023.
View our GMED earnings forecast.

Globus Medical will be holding an earnings conference call on Tuesday, February 21st at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link.

Globus Medical, Inc. (NYSE:GMED) posted its quarterly earnings results on Thursday, November, 4th. The medical device company reported $0.50 EPS for the quarter, topping the consensus estimate of $0.45 by $0.05. The medical device company earned $229.72 million during the quarter, compared to the consensus estimate of $228.28 million. Globus Medical had a trailing twelve-month return on equity of 11.59% and a net margin of 15.55%. Globus Medical's revenue for the quarter was up 6.3% on a year-over-year basis. During the same period last year, the business posted $0.49 earnings per share.

Globus Medical issued an update on its FY 2022 earnings guidance on Thursday, December, 8th. The company provided earnings per share guidance of $2.03-$2.03 for the period, compared to the consensus estimate of $2.10. The company issued revenue guidance of $1.02 billion-$1.02 billion, compared to the consensus revenue estimate of $1.02 billion.

47 employees have rated Globus Medical Chief Executive Officer David Demski on Glassdoor.com. David Demski has an approval rating of 61% among the company's employees. This puts David Demski in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Globus Medical investors own include NVIDIA (NVDA), Shopify (SHOP), CrowdStrike (CRWD), Okta (OKTA), Trade Desk (TTD), Block (SQ), Tesla (TSLA), Teladoc Health (TDOC), Zoom Video Communications (ZM) and Mastercard (MA).

Globus Medical trades on the New York Stock Exchange (NYSE) under the ticker symbol "GMED."

Globus Medical's stock is owned by a number of institutional and retail investors. Top institutional investors include Geneva Capital Management LLC (1.43%), Paradigm Capital Management Inc. NY (0.67%), Boston Trust Walden Corp (0.66%), Pembroke Management LTD (0.59%), Allspring Global Investments Holdings LLC (0.40%) and Envestnet Asset Management Inc. (0.38%). Insiders that own company stock include Daniel T Scavilla, Daniel T Scavilla, David D Davidar, David M Demski, James R Tobin, James R Tobin, Keith W Pfeil, Keith W Pfeil, Kelly Huller and Robert Andrew Douglas.
View institutional ownership trends.

Shares of GMED stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of GMED stock can currently be purchased for approximately $77.88.

Globus Medical (NYSE:GMED) has a market capitalization of $7.78 billion and generates $958.10 million in revenue each year. The medical device company earns $149.19 million in net income (profit) each year or $1.51 on an earnings per share basis.

The company employs 2,400 workers across the globe.

Globus Medical's mailing address is 2560 GENERAL ARMISTEAD AVENUE, AUDUBON PA, 19403. The official website for the company is www.globusmedical.com. The medical device company can be reached via phone at (610) 930-1800, via email at investors@globusmedical.com, or via fax at 610-930-2042.